MTOR and plasma cell myeloma: For example, PIM2 targets the TSC2 protein and enhances the mTOR‐C1 pathway to maintain cell growth in multiple myeloma, representing an important target in the treatment of tumor progression and bone loss in myeloma (Hiasa et al., 2015; Lu et al., 2013).